Immuneering Corporation (NASDAQ:IMRX) Stock Has Consensus Target Price of $15.71 According to Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $15.71.

IMRX has been the topic of several research reports. UBS Group set a $14.00 price target on Immuneering in a research note on Thursday, August 6th. Cantor Fitzgerald started coverage on Immuneering in a research report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of Immuneering in a research note on Thursday, August 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, September 21st. Finally, Chardan Capital upgraded Immuneering to a “strong-buy” rating in a report on Monday, August 3rd.

Institutional Investors Weigh In On Immuneering

A number of large investors have recently modified their holdings of IMRX. PVG Asset Management Corp acquired a new stake in shares of Immuneering in the first quarter valued at about $773,000. Empery Asset Management LP purchased a new position in shares of Immuneering in the fourth quarter worth about $17,601,000. 683 Capital Management LLC purchased a new position in shares of Immuneering in the fourth quarter worth about $992,000. DCF Advisers LLC acquired a new position in Immuneering during the fourth quarter worth about $1,415,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Immuneering during the second quarter worth about $34,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Stock Performance

IMRX stock opened at $3.94 on Friday. Immuneering has a 12-month low of $3.60 and a 12-month high of $8.48. The stock has a market cap of $254.92 million, a price-to-earnings ratio of -3.79 and a beta of 0.46. The business’s 50-day moving average is $4.61 and its 200 day moving average is $4.85.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.01). As a group, equities analysts forecast that Immuneering will post -1.09 EPS for the current fiscal year.

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancers driven by abnormal signaling through the RAS/MAPK pathway. The company applies computational biology and its Deep Cyclic Inhibition approach to design therapies intended to provide sustained pathway suppression while allowing normal cells periods of recovery.

Immuneering’s lead product candidate, IMM-1-104, is an oral therapy being developed for patients with RAS-mutated solid tumors, including pancreatic cancer.